Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist.
Beijing, Beijing Municipality, 100191, China
NCT Number: NCT05369689
This study aims to assess multimodal Radiomics-based prediction model for prognostic prediction in spinal tumors.
Trial opening soon.
Get Notified18 year–80 year
All sexes
Observational
Beijing, Beijing Municipality, 100191, China
Sensitivity for prediction recurrence and survival of currently available prognostic scores is limited. This study proposes to establish a multimodal radiomics model for identifying tumor recurrence and prognostic prediction of spinal tumors. The study will investigate the relationship between the radiomics and the tumor microenvironment. The study includes the construction of multimodal radiomics-based prediction model and the validation of the prediction model.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
A diagnosis of spinal tumors for which SBRT is appropriate Karnofsky Performance Status >60 Life expectancy of at least 3 months No contraindication to undergoing MR imaging Age >18 Complete the CT MRI or PET-CT examination before and after treatment Accept stereotactic radiosurgery
Exclusion criteria
Subjects unable to undergo MRI (includes non-MRI compatible material or devices and severe claustrophobia) Subjects with prior procedural intervention to the involved vertebral body that would result in artifact (kyphoplasty, screw and/or rod placement); minimally invasive surgery without instrumentation of the involved vertebral body and instrumentation immediately above or below the index lesion is allowed.
Subjects with spinal cord compression; minimally invasive "separation" surgery to first resect the epidural component is allowed Pregnant or breast-feeding women Allergy to standard IV contrast agents used in MRI
As this is a prognosis evaluation study, there are no interventions.
Time frame: 1 years
progression-free survival
Time frame: 1 years
defined as the time from the beginning of diagnosis of spinal tumors to the death with any causes
Time frame: 3 months
objective response rate
Time frame: 3 months
disease control rate
Time frame: 1 year
defined as time between randomization and the time of any recurrence of ipsilateral chest, breast, regional lymph node recurrence, distant metastases, or death occurred
Contact information is provided by the study sponsor or research team.
Zhuang Hongqing
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06466720
Brain Diseases, Brain Metastases
Nottingham, Nottinghamshire, United Kingdom
View Trial DetailsNCT07685938
Breast Cancer, Breast Diseases
Chapel Hill, North Carolina, United States
View Trial DetailsNCT07527884
Central Nervous System Diseases, Central Nervous System Neoplasms
View Trial DetailsNCT05396222
Central Nervous System Diseases, Central Nervous System Neoplasms
Taipei, Taiwan
View Trial Details